How does B7-33 work?
Single-chain peptide derivative of relaxin that retains binding to relaxin receptor RXFP1 with anti-fibrotic signaling, but lacks the cardiovascular receptor crosstalk responsible for relaxin's hypotensive effect. In plain terms, B7-33 is a compound aimed at reducing scar-tissue buildup (fibrosis). A single-chain peptide derivative of relaxin, designed to retain anti-fibrotic activity without the cardiovascular side profile of full relaxin. Pre-clinical / early human research. Mechanistic detail like this comes largely from preclinical and early research, the human picture is limited.
What people use it for
- Researchers studying fibrotic disease pathways
- Cardiovascular-research context only
- Educational reference, not for community use
References
- B7-33, single-chain peptide derivative of relaxin retains anti-fibrotic activity without hemodynamic effects — Hossain MA et al., Chem Sci, 2016
- B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin) — Marshall SA, O'Sullivan K, Ng HH, et al., European Journal of Pharmacology, 2017
- Single chain peptide agonists of relaxin receptors — Praveen P, Kocan M, Valkovic A, et al., Molecular and Cellular Endocrinology, 2019
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on B7-33
Last updated 2026-06-06.